Joseph Brito III, MD
Associate Professor TermCards
About
Research
Publications
2024
Pathologic prostate cancer grade concordance among high-resolution micro-ultrasound, systematic transrectal ultrasound and MRI fusion biopsy
Lokeshwar S, Choksi A, Smani S, Kong V, Sundaresan V, Sutherland R, Brito J, Renzulli J, Sprenkle P, Leapman M. Pathologic prostate cancer grade concordance among high-resolution micro-ultrasound, systematic transrectal ultrasound and MRI fusion biopsy. Urologic Oncology Seminars And Original Investigations 2024 PMID: 39521675, DOI: 10.1016/j.urolonc.2024.10.018.Peer-Reviewed Original ResearchMRI-TRUSMRI-TRUS fusionImage-guided biopsyFusion biopsyGG upgradingTRUS biopsyBiopsy strategyBiopsy typeNo significant differencePathological concordanceBiopsy techniqueHigh-resolution micro-ultrasoundMRI-TRUS fusion biopsyMultivariate logistic-regression analysisMRI fusion biopsySystematic transrectal ultrasoundProstate cancer patientsSignificant differenceMicro-ultrasoundLogistic-regression analysisMultivariable-analysisPathological downgradingPathological upgradingRandomized controlled trialsProstate biopsyManagement strategies for radio-recurrent prostate cancer: a comprehensive review
Rahman S, Kim H, Webb L, Diaz G, Leapman M, Sprenkle P, Brito J, Renzulli J, Martin T, Kenney P, Kim I. Management strategies for radio-recurrent prostate cancer: a comprehensive review. Translational Cancer Research 2024, 0: 0-0. PMID: 39697737, PMCID: PMC11651831, DOI: 10.21037/tcr-24-245.Peer-Reviewed Original ResearchRisk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy
Smani S, Sundaresan V, Lokeshwar S, Choksi A, Carbonella J, Brito J, Renzulli J, Sprenkle P, Leapman M. Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 981-996. PMID: 39280242, PMCID: PMC11390291, DOI: 10.37349/etat.2024.00259.Peer-Reviewed Original ResearchGleason score upgradingProstate-specific antigenRisk factorsMagnetic resonance imagingRadical prostatectomyScore upgradingAssociated with Gleason score upgradingBiopsy to radical prostatectomyHigher-risk prostate cancerPatients treated with surgeryProstate magnetic resonance imagingClinically localized diseaseGleason grade groupLow-risk diseaseRecognition of risk factorsBody mass indexGleason upgradingFinal pathologyProstate volumeProstate biopsySource of diagnostic uncertaintyBiopsy coresLocalized diseaseProstate cancerInitial managementThe effect of a fermented soy beverage among patients with localized prostate cancer prior to radical prostatectomy
Lokeshwar S, Ali A, Weiss T, Reynolds J, Shuch B, Ferencz T, Kyriakides T, Mehal W, Brito J, Renzulli J, Leapman M. The effect of a fermented soy beverage among patients with localized prostate cancer prior to radical prostatectomy. BMC Urology 2024, 24: 102. PMID: 38702664, PMCID: PMC11067086, DOI: 10.1186/s12894-024-01483-y.Peer-Reviewed Original ResearchConceptsEnd-of-studyProstate cancerRadical prostatectomyTreatment armsDouble-blind randomized trialProstate cancer characteristicsSurgical margin statusLocalized prostate cancerFACT-P scoresBaseline to end-of-studySerum PSACAPRA scoreGleason scorePSA levelsPlacebo-controlledMedium-chain triglyceridesPrimary endpointIntermediate riskClinical stageMargin statusSerum testosteroneRandomization armFACT-PRisk strataITT analysisMP58-01 A RANDOMIZED CONTROLLED TRIAL OF A FERMENTED SOY BEVERAGE AMONG PATIENTS WITH LOCALIZED PROSTATE CANCER PRIOR TO RADICAL PROSTATECTOMY
Lokeshwar S, Choksi A, Ali A, Weiss T, Reynolds J, Shuch B, Ferencz T, Kyriakides T, Brito J, Renzulli J, Leapman M. MP58-01 A RANDOMIZED CONTROLLED TRIAL OF A FERMENTED SOY BEVERAGE AMONG PATIENTS WITH LOCALIZED PROSTATE CANCER PRIOR TO RADICAL PROSTATECTOMY. Journal Of Urology 2024, 211: e947. DOI: 10.1097/01.ju.0001008852.83523.41.01.Peer-Reviewed Original ResearchA0305 Pathologic gleason upgrading following high-resolution micro-ultrasound, conventional ultrasound and MRI fusion biopsy techniques: A comparative study
Lokeshwar S, Choksi A, Smani S, Kong V, Sundaresan V, Brito J, Renzulli J, Sprenkle P, Michael M. A0305 Pathologic gleason upgrading following high-resolution micro-ultrasound, conventional ultrasound and MRI fusion biopsy techniques: A comparative study. European Urology 2024, 85: s1101. DOI: 10.1016/s0302-2838(24)00884-4.Peer-Reviewed Original ResearchAssociation between pelvic lymph node dissection and survival among patients with prostate cancer treated with radical prostatectomy
Kim I, Wang A, Corpuz G, Sprenkle P, Leapman M, Brito J, Renzulli J, Kim I. Association between pelvic lymph node dissection and survival among patients with prostate cancer treated with radical prostatectomy. Prostate International 2024, 12: 70-78. PMID: 39036758, PMCID: PMC11255894, DOI: 10.1016/j.prnil.2024.01.002.Peer-Reviewed Original ResearchPelvic lymph node dissectionBenefit of pelvic lymph node dissectionGleason grade groupLymph node dissectionProstate cancer patientsRadical prostatectomyNode dissectionProstate cancer treated with radical prostatectomyCancer patientsAssociated with improved OSTime of radical prostatectomyGrade groupSurvival of prostate cancer patientsMedian PSA valuePre-operative characteristicsProstate cancer-specificTime of RPLog-rank testKaplan-Meier curvesPSA valuesSurvival benefitProstate cancerMedian ageClinical benefitCancer-specific
2020
PT417 National variation in lymph node dissection and pathological yield at the time of radical cystectomy
Abello A, Brito J, Sprenkle P, Kenney P, Renzulli J, Leapman M. PT417 National variation in lymph node dissection and pathological yield at the time of radical cystectomy. European Urology Open Science 2020, 19: e2286. DOI: 10.1016/s2666-1683(20)34151-3.Peer-Reviewed Original ResearchMP61-12 NATIONAL VARIATION IN LYMPH NODE DISSECTION AND PATHOLOGICAL YIELD AT THE TIME OF RADICAL CYSTECTOMY
Abello* A, Nawaf C, Brito J, Sprenkle P, Kenney P, Renzulli J, Leapman M. MP61-12 NATIONAL VARIATION IN LYMPH NODE DISSECTION AND PATHOLOGICAL YIELD AT THE TIME OF RADICAL CYSTECTOMY. Journal Of Urology 2020, 203: e939-e940. DOI: 10.1097/ju.0000000000000936.012.Peer-Reviewed Original Research
2018
MP18-20 EX-VIVO TARGETING OF UPPER TRACT UROTHELIAL CARCINOMA USING A NOVEL PHLIP – ICG CONSTRUCT
Brito J, Golijanin B, Pereira J, Amin A, Golijanin D. MP18-20 EX-VIVO TARGETING OF UPPER TRACT UROTHELIAL CARCINOMA USING A NOVEL PHLIP – ICG CONSTRUCT. Journal Of Urology 2018, 199: e221. DOI: 10.1016/j.juro.2018.02.596.Peer-Reviewed Original Research
Clinical Care
Overview
Joseph M. Brito III, MD, is a urologist who enjoys providing the most advanced urologic care to each patient he sees. “The science behind urology is constantly improving, giving patients treatment options that didn't exist even in the recent past,” says Dr. Brito, who sees patients in Lawrence & Memorial Hospital’s New London location, which is part of Yale New Haven Health. He provides general urologic care and minimally invasive techniques for managing prostate, bladder, and kidney cancers.
“As urologists, we are generally early adopters of technology,” he says. “I derive a great sense of satisfaction in being able to bring the most cutting-edge techniques to our patients to improve their lives in a meaningful way.”
For example, Yale Medicine urologists perform MRI/US Fusion prostate biopsy, utilizing the Artemis system; robotic surgery for both benign and malignant conditions of the prostate kidneys and bladder; and minimally invasive treatment options for kidney stones, prostatic enlargement, and urinary obstruction.
Today, many urologic conditions can be surgically managed in minimally invasive ways, meaning patients experience less blood loss, spend less time in the hospital, and recover faster, he explains.
While helping manage urologic conditions, Dr. Brito has the opportunity to get to know his patients as individuals. “We are fortunate to work in a field where we are following patients for months and years at a time, and I find it rewarding to provide care to patients throughout their lives,” says Dr. Brito, who is also an assistant professor of urology at Yale School of Medicine.
Clinical Specialties
Fact Sheets
Kidney Cancer
Learn More on Yale MedicineBlood in the Urine (Hematuria)
Learn More on Yale MedicineJelmyto®
Learn More on Yale MedicineUrinary Tract Infection
Learn More on Yale Medicine
Board Certifications
Urology
- Certification Organization
- AB of Urology
- Original Certification Date
- 2020
Yale Medicine News
News & Links
News
- January 16, 2025
Yale Urology Research [Q4: October-December 2024]
- November 19, 2024
2nd Annual Yale Urology Bulldog Debates Recap
- October 30, 2024
Yale Urology Research [Q3: July-September 2024]
- July 31, 2024
Yale Urology Research [Q2: April-June 2024]
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.